Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
672 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04876313 | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)(NURE-Combo) | unknown | Phase 2 | 29 | IRCCS San RaffaeleOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04602702 | Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors(PDXovo) | unknown | — | 50 | Sunnybrook Health Sciences CentreOTHER |
| 1 |
| Apr 5, 2022 |
| clinicaltrials |
| NCT02994758 | Development of Diagnostics and Treatment of Urological Cancers(DEDUCER) | unknown | N/A | 100 | Helsinki University Central HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02535650 | Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma | unknown | Phase 2 | 19 | Samsung Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05262413 | A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) | unknown | Phase 1 / Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 2, 2022 | clinicaltrials |
| NCT03177239 | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)(UNISoN) | unknown | Phase 2 | 85 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05220124 | A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma | unknown | Phase 4 | 190 | Tianjin Medical University Second HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04603846 | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05170555 | Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617 | unknown | N/A | 40 | Peking Union Medical College HospitalOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT01141816 | Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Kidney Lesions | unknown | N/A | 30 | St. Joseph's Healthcare HamiltonOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT05160285 | Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma | unknown | Phase 2 | 29 | YULISUOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04839510 | A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer | unknown | Phase 2 | 58 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02689167 | Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma(SURF) | unknown | Phase 2 | 226 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 29, 2021 | clinicaltrials |
| NCT05135832 | Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma(PRORECECA) | unknown | N/A | 174 | Herlev and Gentofte HospitalOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT05124431 | Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma(ALTER-UC-001) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT04730232 | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable | unknown | Phase 2 | 63 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05097404 | Clinical Utility of VI-RADS in Diagnosis of MIBC | unknown | — | 73 | Samsung Medical CenterOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT05086666 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | unknown | Phase 1 / Phase 2 | 108 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT02497599 | Intraoperative Dual-modality Imaging in Renal Cell Carcinoma | unknown | Phase 1 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT01444807 | Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases | unknown | Phase 2 | 132 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04432909 | A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up | unknown | — | 500 | Changhai HospitalOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT05043662 | UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis. | unknown | — | 110 | Changhai HospitalOTHER | 1 | Sep 14, 2021 | clinicaltrials |
| NCT04534998 | Robotic-assisted vs. Open Partial Nephrectomy(ROBOCOP) | unknown | Phase 2 | 50 | Universitätsmedizin MannheimOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT05030077 | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma | unknown | Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT05027412 | En Bloc TURBT With Collins Loop vs Conventional TURBT(TURBT) | unknown | N/A | 80 | Hospital Universitario de FuenlabradaOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT04815629 | Outcome of Radiation Therapy in Urinary Bladder Squampus Cell Carcinoma | unknown | — | 40 | Assiut UniversityOTHER | 0 | Aug 18, 2021 | clinicaltrials |
| NCT04267575 | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites | unknown | N/A | 20 | Jerome Canady, M.D.OTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04995016 | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma(PANDORA) | unknown | Phase 2 | 18 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04177056 | Stereotactic Body Radiotherapy for Osseous Low Alpha-Beta Resistant Metastases for Pain Relief(SOLAR-P) | unknown | N/A | 40 | Hamilton Health Sciences CorporationOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT04871334 | Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 1 | 76 | Shandong TheraWisdom Biopharma Co., Ltd.INDUSTRY | 1 | Jul 23, 2021 | clinicaltrials |
| NCT04966130 | Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder. | unknown | — | 96 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 19, 2021 | clinicaltrials |
| NCT04958473 | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer(SAARCC) | unknown | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT04909775 | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04891055 | Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)(I-Rene) | unknown | — | 90 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT03624673 | Endoscopic Robot-Assisted Simple Enucleation Versus Standard Robot-Assisted Partial Nephrectomy in the Treatment of T1 Renal Cell Carcinoma | unknown | N/A | 380 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04798963 | The Evaluation of Functional Parenchymal Volume and Split Renal Function Before and After Partial Nephrectomy | unknown | N/A | 60 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT03824691 | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"(ARCADIA) | unknown | Phase 2 | 122 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT04666220 | VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma | unknown | — | 180 | Humanitas Clinical and Research CenterOTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT04383067 | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | unknown | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04714697 | Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma | unknown | Phase 2 | 201 | Asan Medical CenterOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT03738488 | 3D-biomodels for Surgical Planning in Patients With Renal Cancer and Vascular Involvement(3DUrologia) | unknown | N/A | 10 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT04686149 | a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients | unknown | — | 39 | Yonsei UniversityOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT04134182 | Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. | unknown | Phase 2 | 8 | Kidney Cancer Research BureauOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04644432 | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma(INDIGO) | unknown | Phase 2 | 30 | Herlev and Gentofte HospitalOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04211012 | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | unknown | Phase 2 | 30 | Jun GuoOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04609293 | Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma | unknown | — | 30 | Peking University First HospitalOTHER | 0 | Oct 30, 2020 | clinicaltrials |
| NCT04244136 | Residual Normal Renal Parenchymal and Tumor Volume in Tumor Surgeries | unknown | — | 32 | Assiut UniversityOTHER | 0 | Oct 8, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2022source: clinicaltrials